Tobias Weizel, Novocure’s General Manager Germany, leads the company’s commercial business in Germany and said he feels lucky to be a part of Novocure’s mission of bringing a profoundly different cancer treatment to patients worldwide.
Our second generation Optune System is smaller and less than half the weight of our first generation Optune System. See more on the innovation behind our redesigned Tumor Treating Fields delivery system.
Our Device Support Specialists (DSSs) work one-on-one with patients — educating them about the device, and providing technical support and personal contact with Novocure. Learn more about Amy Luton, one of our DSSs in Texas.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.